Announcement

Collapse
No announcement yet.

Front Immunol . Immune responses and transcription landscape of adults with the third dose of homologous and heterologous booster vaccines of COVID-19

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Front Immunol . Immune responses and transcription landscape of adults with the third dose of homologous and heterologous booster vaccines of COVID-19

    Front Immunol


    . 2024 Sep 12:15:1461419.
    doi: 10.3389/fimmu.2024.1461419. eCollection 2024. Immune responses and transcription landscape of adults with the third dose of homologous and heterologous booster vaccines of COVID-19

    Hui Zheng # 1 2 , Cuidan Li # 3 , Xiuyu Zheng # 4 , Hu-Dachuan Jiang 1 , Yuqing Li 5 , Aihua Yao 1 , Xiaolong Li 4 , Feiyu Wang 4 , Wenqing Liu 5 , Xiang Cao 1 , Runjie Qi 5 , Li Chen 1 , Lairun Jin 1 , Fengcai Zhu 1 2 5 , Jingxin Li 1 2 5 , Fei Chen 3



    AffiliationsAbstract

    Background: Heterologous booster vaccines are more effective than homologous booster vaccines in combating the coronavirus disease 2019 (COVID-19) outbreak. However, our understanding of homologous and heterologous booster vaccines for COVID-19 remains limited.
    Methods: We recruited 34 healthy participants from two cohorts who were primed with two-dose inactivated COVID-19 vaccine before, vaccinated with COVID-19 inactivated vaccine and adenovirus-vectored vaccine (intramuscular and aerosol inhalation of Ad5-nCoV) as a third booster dose. We assessed the immune responses of participants before and 14 days after vaccination, including levels of neutralizing antibodies, IgG, and cytokines, and quantified the transcriptional profile of peripheral blood mononuclear cells (PBMCs).
    Results: The Ad5-nCoV group showed a significantly higher neutralizing antibody geometric mean titer (GMT) compared to the ICV group after 14 days of heterologous boosting. The intramuscular Ad5-nCoV group had a GMT of 191.8 (95% CI 129.0, 285.1) compared to 38.1 (95% CI 23.1, 62.8) in the ICV1 group (p<0.0001). The aerosolized Ad5-nCoV group had a GMT of 738.4 (95% CI 250.9-2173.0) compared to 244.0 (95% CI 135.0, 441.2) in the ICV2 group (p=0.0434). Participants in the aerosolized Ad5-nCoV group had median IFN-γ+ spot counts of 36.5 (IQR 15.3-58.8) per 106 PBMCs, whereas, both intramuscular Ad5-nCoV and CoronaVac immunization as the third dose showed lower responses. This suggests that a third dose of booster Ad5-nCoV vaccine (especially aerosolized inhalation) as a heterologous vaccine booster induces stronger humoral and cellular immune responses, which may be more potent against VOCs than the use of inactivated vaccine homologs. In transcriptomic analyses, both aerosolized inhalation/intramuscular injection of the Ad5-nCoV vaccine and inactivated vaccine induced a large number of differentially expressed genes that were significantly associated with several important innate immune pathways including inflammatory responses, regulation of the defense response, and regulation of cytokine production. In addition, we identified crucial molecular modules of protective immunity that are significantly correlated with vaccine type and neutralizing antibodies level.
    Conclusion: This study demonstrated that inhalation/intramuscular injection of the Ad5-nCoV vaccine-mediated stronger humoral and cellular immune responses compared with the inactivated vaccine, and correlated significantly with innate immune function modules, supporting a heterologous booster immunization strategy.

    Keywords: Ad5-nCoV; COVID-19; aerosol inhalation; immunity; intramuscular injection; transcriptome.

Working...
X